Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study

City of Hope Medical Center1 site in 1 country26 target enrollmentNovember 25, 2013

ConditionsRecurrent Prostate Cancer Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Recurrent Prostate Cancer
Sponsor: City of Hope Medical Center
Enrollment: 26
Locations: 1
Primary Endpoint: MTD, defined as the highest dose tested in which fewer than 33% of patients experienced dose limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Status: Active, not recruiting
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed Description

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) with an upper limit of 45 Gray (Gy) in 5 fractions, in the delivery of stereotactic body radiation therapy (SBRT) to the prostate fossa. SECONDARY OBJECTIVES: I. To assess acute and late toxicities from treatment. II. To assess biochemical progression-free survival. III. To collect prospective quality-of-life data related to bowel, urinary, and sexual health. OUTLINE: This is a dose-escalation study. Patients receive 5 fractions of SBRT over 1.5 weeks. After completion of study treatment, patients are followed up at 90 days and then periodically for 3 years.

Registry

clinicaltrials.gov

Start Date

November 25, 2013

End Date

July 28, 2026

Last Updated

5 months ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

City of Hope Medical Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•History of diagnosis of prostate cancer after undergoing prostatectomy
•No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
•Eastern Cooperative Oncology Group (ECOG) performance scale 0-2
•Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable
•Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry
•PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion
•All subjects must have the ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

•Patients should not have any uncontrolled illness including ongoing or active infection
•Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy
•Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years
•Study-specific exclusions:
•History of prior radiation to the pelvis
•History of uncontrolled inflammatory bowel disease
•Unable to comply with radiation therapy procedures
•Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Outcomes

Primary Outcomes

MTD, defined as the highest dose tested in which fewer than 33% of patients experienced dose limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Time Frame: 90 days

Tables will be created to summarize these toxicities and side effects by dose level.

Secondary Outcomes

Biochemical progression-free survival(Up to 3 years)
Incidence of acute toxicities observed at each dose level graded according to the NCI CTCAE version 4.0(Up to 90 days)
Incidence of late toxicities observed at each dose level graded according to the NCI CTCAE version 4.0(Up to 3 years)
Prospective quality-of-life data related to bowel, urinary, and sexual health using the numerical scores generated from the patient questionnaires(Up to 3 years)